These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacodynamic assessment of the in vivo cyclosporine effect on interleukin-2 production by lymphocytes in kidney transplant recipients. Yoshimura N; Kahan BD Transplantation; 1985 Dec; 40(6):661-6. PubMed ID: 3934806 [TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 receptor expression on peripheral blood lymphocytes in association with renal allograft rejection. Reed MH; Shapiro ME; Milford EL; Carpenter CB; Kirkman RL Transplantation; 1989 Sep; 48(3):361-6. PubMed ID: 2571202 [TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982 [TBL] [Abstract][Full Text] [Related]
8. Function and surface phenotype of T lymphocytes infiltrating renal allografts in nonhuman primates treated with monoclonal antibodies. Nocera A; Cosimi AB; Colvin RB; Gesner ML; Fuller TC Transplantation; 1989 Nov; 48(5):732-41. PubMed ID: 2573179 [TBL] [Abstract][Full Text] [Related]
14. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3. Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099 [TBL] [Abstract][Full Text] [Related]
15. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Jiang H; Wynn C; Pan F; Ebbs A; Erickson LM; Kobayashi M Transplantation; 2002 Jun; 73(11):1808-17. PubMed ID: 12085006 [TBL] [Abstract][Full Text] [Related]
16. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin. Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143 [TBL] [Abstract][Full Text] [Related]
17. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Benvenisty AI; Cohen D; Stegall MD; Hardy MA Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654 [TBL] [Abstract][Full Text] [Related]
18. Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Yoshimura N; Oka T; Kahan BD Transplantation; 1991 Jan; 51(1):172-6. PubMed ID: 1987687 [TBL] [Abstract][Full Text] [Related]
19. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265 [TBL] [Abstract][Full Text] [Related]
20. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation. Cooper MM; Robbins RC; Goldman CK; Mirzadeh S; Brechbiel MW; Stone CD; Gansow OA; Clark RE; Waldmann TA Transplantation; 1990 Nov; 50(5):760-5. PubMed ID: 2238051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]